NCT00029107View on ClinicalTrials.gov

Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Hepatitis CVasculitis
Interventions
DRUG

Rituximab

anti-CD20 monoclonal antibody

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00029107 - Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis | Biotech Hunter | Biotech Hunter